-
As of early October 2025, the Stratus COVID-19 variant (XFG and XFG.3) has become dominant in the US, causing persistent respiratory symptoms but no increased severity. Meanwhile, Japan faces an unusually early and rapid influenza epidemic, with hospitals filling and schools closing. Experts urge vaccination and hygiene to mitigate these overlapping respiratory threats.
-
England is set to approve cabotegravir, a two-month injectable HIV prevention shot, expanding options for those unable to take daily pills. Zimbabwe will roll out lenacapavir, a twice-yearly prophylactic, amid debates over cost and safety. Both developments mark significant advances in HIV prevention efforts.
-
Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and Kenvue, alleging deceptive marketing of Tylenol to pregnant women amid unproven claims linking the drug to autism. The case follows recent political statements by Trump and Kennedy suggesting a connection, which medical experts strongly dispute. The companies defend Tylenol's safety, citing scientific consensus.
-
As of late November 2025, the US, UK, Canada, and Japan face an early, severe flu season driven by the H3N2 subclade K variant, which has mutated beyond current vaccine strains. Hospital admissions and flu cases, especially among children and vulnerable groups, are rising. Concurrently, norovirus infections are doubling nationwide, with health officials urging hygiene and vaccination to mitigate risks.
-
A cold front has brought sleet and snow across the UK, especially in northern regions, causing travel disruptions, power outages, and potential community isolation. Warnings remain in effect until Thursday night, with snow totals reaching up to 25cm in some areas. Authorities advise caution for travelers and residents.